Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDesonide
Identification
- Name
- Desonide
- Accession Number
- DB01260
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem]
- Structure
Structure for DB01260 (Desonide)
- Synonyms
- 11beta,21-Dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
- 11beta,21-Dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
- 11beta,21-Dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
- 16alpha-Hydroxyprednisole-16,17-acetonide
- 16alpha-Hydroxyprednisolone-16alpha,17-acetonide
- 16alpha,17alpha-Isopropylidenedioxyprednisolone
- Desfluorotriamcinolone acetonide
- Desonida
- Desonidum
- External IDs
- D-2083 / D2083
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Desocort Cream 0.05% Cream .05 % Topical Galderma 1994-12-31 2007-08-02 Canada 
Desocort Lotion - 0.05% Lotion .05 % Topical Galderma 1994-12-31 2016-08-04 Canada Desocort Ointment - 0.05% Ointment .05 % Topical Galderma 1994-12-31 2016-08-04 Canada Desonate Gel .5 mg/g Topical Bayer 2006-10-20 Not applicable US 
Desonate Gel .5 mg/g Topical Intendis Inc. 2010-01-28 Not applicable US Desonide Cream .5 mg/g Topical Rebel Distributors 2006-04-11 Not applicable US Desonide Cream .5 mg/g Topical Perrigo New York Inc. 2006-04-11 Not applicable US Desonide Cream .5 mg/g Topical Physicians Total Care, Inc. 2006-04-11 Not applicable US Desonide Ointment .5 mg/g Topical Perrigo New York Inc. 2006-08-22 Not applicable US Desonide Ointment .5 mg/g Topical Physicians Total Care, Inc. 2006-06-21 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Desonide Cream .5 mg/g Topical North Star Rx Llc 1992-06-30 Not applicable US Desonide Lotion .5 mg/mL Topical Taro Pharmaceuticals U.S.A., Inc. 2014-10-31 Not applicable US Desonide Ointment .5 mg/g Topical E. Fougera & CO., A division of Fougera Pharmaceuticals Inc. 2001-03-12 Not applicable US Desonide Cream .5 mg/g Topical Proficient Rx LP 2013-08-01 Not applicable US Desonide Cream .5 mg/g Topical Actavis Pharma Company 2013-08-01 Not applicable US Desonide Ointment .5 mg/g Topical Versa Pharm, Inc. An Akorn Company 2017-09-01 Not applicable US Desonide Lotion .5 mg/g Topical Owen Laboratories 1984-12-14 Not applicable US Desonide Ointment .5 mg/g Topical Taro Pharmaceuticals U.S.A., Inc. 1994-08-03 Not applicable US Desonide Cream .5 mg/g Topical Rebel Distributors 1992-06-30 Not applicable US Desonide Lotion .5 mg/mL Topical Actavis Pharma Company 2009-05-28 Not applicable US - International/Other Brands
- Desocort (Galderma) / Tridesilon (Bayer)
- Categories
- UNII
- J280872D1O
- CAS number
- 638-94-8
- Weight
- Average: 416.5073
Monoisotopic: 416.219888756 - Chemical Formula
- C24H32O6
- InChI Key
- WBGKWQHBNHJJPZ-LECWWXJVSA-N
- InChI
- InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
- IUPAC Name
- (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
- SMILES
- [H][[email protected]@]12C[[email protected]@]3([H])[[email protected]]4([H])CCC5=CC(=O)C=C[[email protected]]5(C)[[email protected]@]4([H])[[email protected]@H](O)C[[email protected]]3(C)[[email protected]@]1(OC(C)(C)O2)C(=O)CO
Pharmacology
- Indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
- Structured Indications
- Pharmacodynamics
Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
- Mechanism of action
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Target Actions Organism AGlucocorticoid receptor agonistHuman - Absorption
Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desonide. Investigational 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Desonide is combined with 1,10-Phenanthroline. Experimental Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desonide. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Desonide. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desonide. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Desonide. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Desonide. Approved, Withdrawn Aldesleukin Desonide may decrease the antineoplastic activities of Aldesleukin. Approved Almasilate The bioavailability of Desonide can be decreased when combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Desonide. Experimental Aloglutamol The bioavailability of Desonide can be decreased when combined with Aloglutamol. Approved Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Desonide. Experimental Aluminium The bioavailability of Desonide can be decreased when combined with Aluminium. Approved, Investigational Aluminium acetoacetate The bioavailability of Desonide can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Desonide can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Desonide can be decreased when combined with Aluminum hydroxide. Approved, Investigational Ambenonium The risk or severity of adverse effects can be increased when Desonide is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desonide. Approved Amiodarone The serum concentration of Desonide can be increased when it is combined with Amiodarone. Approved, Investigational Amphotericin B Desonide may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Desonide. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Desonide. Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when Desonide is combined with Anthrax immune globulin human. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Desonide. Approved, Investigational Apalutamide The serum concentration of Desonide can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Desonide. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Desonide. Approved, Investigational Aprepitant The serum concentration of Desonide can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of Desonide can be increased when it is combined with Atazanavir. Approved, Investigational Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Desonide. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Desonide. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Desonide. Approved Azosemide Desonide may increase the hypokalemic activities of Azosemide. Investigational Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Desonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Desonide is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Desonide. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when Desonide is combined with BCG vaccine. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Desonide. Experimental Bendroflumethiazide Desonide may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Desonide. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desonide. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Desonide. Approved, Investigational Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Desonide. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Desonide. Experimental Bismuth Subcitrate The bioavailability of Desonide can be decreased when combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The bioavailability of Desonide can be decreased when combined with Bismuth subnitrate. Approved, Experimental Boceprevir The serum concentration of Desonide can be increased when it is combined with Boceprevir. Approved, Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Desonide. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Desonide. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Desonide. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Desonide. Experimental Bumetanide Desonide may increase the hypokalemic activities of Bumetanide. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Desonide. Approved, Nutraceutical Calcium Carbonate The bioavailability of Desonide can be decreased when combined with Calcium Carbonate. Approved, Investigational Calcium silicate The bioavailability of Desonide can be decreased when combined with Calcium silicate. Experimental Capromab pendetide Desonide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Carbamazepine The serum concentration of Desonide can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desonide. Experimental, Investigational Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Desonide. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Desonide. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Desonide. Approved, Investigational Ceritinib Desonide may increase the hyperglycemic activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Desonide. Approved, Investigational, Vet Approved Chlorothiazide Desonide may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Desonide can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Chlorthalidone Desonide may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desonide. Approved Cinoxacin The risk or severity of adverse effects can be increased when Desonide is combined with Cinoxacin. Approved, Investigational, Withdrawn Clarithromycin The serum concentration of Desonide can be increased when it is combined with Clarithromycin. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Desonide. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Desonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Cobicistat The serum concentration of Desonide can be increased when it is combined with Cobicistat. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens The serum concentration of Desonide can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desonide. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Desonide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when Desonide is combined with Coumaphos. Vet Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Desonide. Approved, Investigational Cyclopenthiazide Desonide may increase the hypokalemic activities of Cyclopenthiazide. Experimental Daidzein The serum concentration of Desonide can be increased when it is combined with Daidzein. Experimental Danazol Desonide may increase the fluid retaining activities of Danazol. Approved Darunavir The serum concentration of Desonide can be increased when it is combined with Darunavir. Approved Decamethonium The risk or severity of adverse effects can be increased when Desonide is combined with Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when Desonide is combined with Deferasirox. Approved, Investigational Demecarium The risk or severity of adverse effects can be increased when Desonide is combined with Demecarium. Approved Dersalazine The risk or severity of adverse effects can be increased when Dersalazine is combined with Desonide. Investigational Dichlorvos The risk or severity of adverse effects can be increased when Desonide is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Desonide. Approved, Vet Approved Dienestrol The serum concentration of Desonide can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of Desonide can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Desonide. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Desonide. Approved, Investigational Distigmine The risk or severity of adverse effects can be increased when Desonide is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when Desonide is combined with Donepezil. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Desonide. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Desonide. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Desonide. Investigational Echothiophate The risk or severity of adverse effects can be increased when Desonide is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when Desonide is combined with Edrophonium. Approved Enoxacin The risk or severity of adverse effects can be increased when Desonide is combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of Desonide can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Desonide can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Desonide. Approved Epitizide Desonide may increase the hypokalemic activities of Epitizide. Experimental Equol The serum concentration of Desonide can be increased when it is combined with Equol. Investigational Estradiol The serum concentration of Desonide can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Desonide can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Desonide can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Desonide can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of Desonide can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of Desonide can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of Desonide can be increased when it is combined with Estrone. Approved Etacrynic acid Desonide may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Desonide. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Desonide. Experimental Ethinyl Estradiol The serum concentration of Desonide can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Desonide. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Desonide. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desonide. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desonide. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Desonide. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Desonide. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Desonide. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desonide. Approved Fenthion The risk or severity of adverse effects can be increased when Desonide is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Desonide. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Desonide. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Desonide. Experimental Fleroxacin The risk or severity of adverse effects can be increased when Desonide is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Desonide. Approved, Withdrawn Flumequine The risk or severity of adverse effects can be increased when Desonide is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Desonide. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desonide. Experimental Fluoxymesterone Desonide may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desonide. Approved, Investigational Fosaprepitant The serum concentration of Desonide can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Desonide can be decreased when it is combined with Fosphenytoin. Approved, Investigational Furosemide Desonide may increase the hypokalemic activities of Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when Desonide is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when Desonide is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Desonide is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Desonide is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Desonide can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when Desonide is combined with GI-5005. Investigational GLPG-0492 Desonide may increase the fluid retaining activities of GLPG-0492. Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Desonide. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Desonide. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desonide. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Desonide is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Desonide is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexestrol The serum concentration of Desonide can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Desonide. Investigational Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Desonide is combined with Human rabies virus immune globulin. Approved Huperzine A The risk or severity of adverse effects can be increased when Desonide is combined with Huperzine A. Approved, Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desonide. Approved, Investigational Hydrochlorothiazide Desonide may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Desonide may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydrotalcite The bioavailability of Desonide can be decreased when combined with Hydrotalcite. Approved, Experimental, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desonide. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desonide. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Desonide. Approved, Investigational Idelalisib The serum concentration of Desonide can be increased when it is combined with Idelalisib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desonide. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of Desonide. Approved Indapamide Desonide may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of Desonide can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Desonide. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Desonide. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Desonide. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when Desonide is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Desonide is combined with INGN 225. Investigational Ipidacrine The risk or severity of adverse effects can be increased when Desonide is combined with Ipidacrine. Experimental Isoflurophate The risk or severity of adverse effects can be increased when Desonide is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Desonide. Approved, Investigational Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Desonide. Withdrawn Itraconazole The serum concentration of Desonide can be increased when it is combined with Itraconazole. Approved, Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Desonide is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Desonide. Experimental Ketoconazole The serum concentration of Desonide can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desonide. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Desonide. Approved Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Desonide. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Desonide. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Desonide. Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Desonide. Experimental Lopinavir The serum concentration of Desonide can be increased when it is combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desonide. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desonide. Approved, Investigational Lumacaftor The serum concentration of Desonide can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desonide. Approved, Investigational Magaldrate The bioavailability of Desonide can be decreased when combined with Magaldrate. Approved, Withdrawn Magnesium hydroxide The bioavailability of Desonide can be decreased when combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The bioavailability of Desonide can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Desonide can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desonide. Approved Magnesium silicate The bioavailability of Desonide can be decreased when combined with Magnesium silicate. Approved, Experimental Magnesium Trisilicate The bioavailability of Desonide can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Desonide is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Desonide. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desonide. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desonide. Approved Mefloquine The risk or severity of adverse effects can be increased when Desonide is combined with Mefloquine. Approved, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Desonide. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Desonide is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Desonide. Approved Mesterolone Desonide may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Desonide can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Desonide. Approved, Investigational, Withdrawn Methallenestril The serum concentration of Desonide can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Desonide is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Desonide may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desonide. Approved, Vet Approved Methyltestosterone Desonide may increase the fluid retaining activities of Methyltestosterone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Desonide is combined with Metoclopramide. Approved, Investigational Metolazone Desonide may increase the hypokalemic activities of Metolazone. Approved Mifepristone The therapeutic efficacy of Desonide can be decreased when used in combination with Mifepristone. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Desonide is combined with Minaprine. Approved Mitotane The serum concentration of Desonide can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of Desonide. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Desonide. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Desonide. Experimental Moxestrol The serum concentration of Desonide can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desonide. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desonide. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Desonide. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Desonide. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Desonide. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Desonide is combined with Nalidixic Acid. Approved, Investigational Nandrolone Desonide may increase the fluid retaining activities of Nandrolone. Experimental, Investigational Nandrolone decanoate Desonide may increase the fluid retaining activities of Nandrolone decanoate. Approved, Illicit Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Desonide. Approved, Vet Approved Nefazodone The serum concentration of Desonide can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Desonide can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Desonide is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when Desonide is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Desonide. Approved, Investigational Nevirapine The serum concentration of Desonide can be decreased when it is combined with Nevirapine. Approved Nicorandil The risk or severity of adverse effects can be increased when Desonide is combined with Nicorandil. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Desonide. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desonide. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Desonide. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desonide. Investigational Norfloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Norfloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Desonide. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Desonide. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Desonide. Vet Approved Oxandrolone Desonide may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desonide. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Desonide is combined with Oxolinic acid. Experimental Oxymetholone Desonide may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desonide. Approved, Withdrawn Paraoxon The risk or severity of adverse effects can be increased when Desonide is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Desonide. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Desonide. Approved, Investigational Pazufloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Desonide can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Phenobarbital The serum concentration of Desonide can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desonide. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Desonide. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desonide. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Desonide. Approved, Investigational Phenytoin The serum concentration of Desonide can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Desonide is combined with Physostigmine. Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desonide. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Desonide is combined with Pipemidic acid. Experimental Piretanide Desonide may increase the hypokalemic activities of Piretanide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desonide. Approved, Investigational Piromidic acid The risk or severity of adverse effects can be increased when Desonide is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Desonide. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Desonide. Experimental Polyestradiol phosphate The serum concentration of Desonide can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Desonide may increase the hypokalemic activities of Polythiazide. Approved Posaconazole The serum concentration of Desonide can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Desonide. Experimental, Investigational Primidone The serum concentration of Desonide can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Desonide. Experimental Promestriene The serum concentration of Desonide can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Desonide. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Desonide. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Desonide. Experimental Prulifloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Desonide. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Desonide is combined with Pyridostigmine. Approved, Investigational Quinestrol The serum concentration of Desonide can be increased when it is combined with Quinestrol. Approved Quinethazone Desonide may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Desonide is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Desonide. Withdrawn Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Desonide. Approved, Experimental, Investigational Rifabutin The serum concentration of Desonide can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Desonide can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Desonide can be decreased when it is combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Desonide is combined with Rindopepimut. Investigational Rivastigmine The risk or severity of adverse effects can be increased when Desonide is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desonide. Approved, Investigational, Withdrawn Rosoxacin The risk or severity of adverse effects can be increased when Desonide is combined with Rosoxacin. Approved, Investigational Rotavirus Vaccine The risk or severity of adverse effects can be increased when Desonide is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Desonide is combined with Rubella virus vaccine. Approved, Investigational Rufloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Desonide. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desonide. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Desonide is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Desonide is combined with Salmonella typhi ty21a live antigen. Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Desonide. Approved Saquinavir The serum concentration of Desonide can be increased when it is combined with Saquinavir. Approved, Investigational Secoisolariciresinol The serum concentration of Desonide can be increased when it is combined with Secoisolariciresinol. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Desonide. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Desonide. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Desonide. Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Sitafloxacin. Experimental, Investigational Sodium bicarbonate The bioavailability of Desonide can be decreased when combined with Sodium bicarbonate. Approved Sparfloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Sparfloxacin. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Desonide is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Desonide. Investigational St. John's Wort The serum concentration of Desonide can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone Desonide may increase the fluid retaining activities of Stanolone. Illicit, Investigational Stanozolol Desonide may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of Desonide can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desonide. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Desonide. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Desonide. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Desonide. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Desonide can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Desonide can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when Desonide is combined with Tacrine. Investigational, Withdrawn Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desonide. Investigational Tecemotide The risk or severity of adverse effects can be increased when Desonide is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Desonide. Approved, Withdrawn Telithromycin The serum concentration of Desonide can be increased when it is combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Desonide. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desonide. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Desonide. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desonide. Approved Testosterone Desonide may increase the fluid retaining activities of Testosterone. Approved, Investigational Testosterone cypionate The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Desonide. Approved Testosterone enanthate The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Desonide. Approved Testosterone propionate Desonide may increase the fluid retaining activities of Testosterone propionate. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Desonide. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Desonide is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desonide. Approved Tibolone The serum concentration of Desonide can be increased when it is combined with Tibolone. Approved, Investigational Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Desonide. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desonide. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Desonide. Approved Torasemide Desonide may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Desonide. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Desonide. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Desonide is combined with Trichlorfon. Vet Approved Trichlormethiazide Desonide may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Desonide. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desonide. Approved Tromethamine The bioavailability of Desonide can be decreased when combined with Tromethamine. Approved Trovafloxacin The risk or severity of adverse effects can be increased when Desonide is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Desonide is combined with Tubocurarine. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desonide. Approved, Investigational, Withdrawn Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Desonide is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Voriconazole The serum concentration of Desonide can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin Desonide may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Desonide is combined with Yellow Fever Vaccine. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desonide. Approved, Investigational Zeranol The serum concentration of Desonide can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Desonide. Approved, Investigational, Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Desonide. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015389
- KEGG Drug
- D03696
- PubChem Compound
- 5311066
- PubChem Substance
- 46506186
- ChemSpider
- 4470603
- ChEBI
- 204734
- ChEMBL
- CHEMBL1201109
- Therapeutic Targets Database
- DAP001188
- PharmGKB
- PA164776996
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Desonide
- ATC Codes
- S01BA11 — Desonide
- S01BA — Corticosteroids, plain
- S01B — ANTIINFLAMMATORY AGENTS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- D07BB — Corticosteroids, moderately potent, combinations with antiseptics
- D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- AHFS Codes
- 84:06.00 — Anti-inflammatory Agents
- MSDS
- Download (73.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Recruiting Basic Science Healthy Volunteers 1 3 Completed Treatment Atopic Dermatitis (AD) 1 3 Recruiting Treatment Atopic Dermatitis Eczema 1 3 Unknown Status Treatment Atopic Dermatitis (AD) / Dermatitis, Eczematous 1 4 Completed Treatment Atopic Dermatitis (AD) 2 4 Completed Treatment Atopic Dermatitis (AD) / Dermatitis, Eczematous 1 4 Completed Treatment Hyperpigmentation 1 4 Not Yet Recruiting Treatment Psoriasis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Actavis Group
- Ameri-Pac Inc.
- Contract Pharm
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DPT Laboratories Ltd.
- E. Fougera and Co.
- Galderma Laboratories
- Intendis Inc.
- Ivax Pharmaceuticals
- Major Pharmaceuticals
- Medisca Inc.
- Nycomed Inc.
- Palmetto Pharmaceuticals Inc.
- Perrigo Co.
- Pharmedix
- Physicians Total Care Inc.
- Stiefel Labs
- Taro Pharmaceuticals USA
- Dosage forms
Form Route Strength Lotion Topical .05 % Gel Topical .5 mg/g Cream Topical .5 mg/g Lotion Topical .5 mg/g Lotion Topical .5 mg/mL Ointment Topical .5 mg/g Cream Topical 0.05 % Ointment Topical 0.05 % Cream Topical .05 % Ointment Topical .05 % Cream Topical .03 g/60g Cream Topical .5 mg Ointment Topical .5 mg Aerosol, foam Topical .5 mg/g Aerosol, foam Topical 0.05 % - Prices
Unit description Cost Unit DesOwen Lot w/Cetaphil Cream 0.05% Kit Box 255.84USD box Desowen 0.05% ointment kit 217.2USD kit Desowen 0.05% cream kit 212.4USD kit DesOwen 0.05% Lotion 118ml Bottle 183.17USD bottle Desonide powder 152.39USD g DesOwen 0.05% Lotion 59ml Bottle 123.38USD bottle Desonide 0.05% Lotion 118ml Bottle 76.75USD bottle Desonide 0.05% Lotion 59ml Bottle 50.86USD bottle Desonide 0.05% Ointment 60 gm Tube 41.76USD tube Desonide 0.05% Cream 60 gm Tube 41.48USD tube Desonide 0.05% Ointment 15 gm Tube 16.09USD tube Desonide 0.05% Cream 15 gm Tube 16.07USD tube Desowen 0.05% cream 2.43USD g Desonide 0.05% cream 0.81USD g Desocort 0.05 % Ointment 0.32USD g Pms-Desonide 0.05 % Cream 0.28USD g Pms-Desonide 0.05 % Ointment 0.28USD g Desocort 0.05 % Lotion 0.16USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US8460641 No 2008-11-05 2028-11-05 US US8962000 No 2005-08-31 2025-08-31 US US6730288 No 1999-09-08 2019-09-08 US US7029659 No 1999-09-08 2019-09-08 US US6387383 No 2000-08-03 2020-08-03 US US9492384 No 2005-08-31 2025-08-31 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 257-260 Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc. water solubility Practically insoluble Not Available logP 1.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0594 mg/mL ALOGPS logP 2.31 ALOGPS logP 1.9 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 13.74 ChemAxon pKa (Strongest Basic) -2.9 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 93.06 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 112.06 m3·mol-1 ChemAxon Polarizability 44.77 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9764 Blood Brain Barrier + 0.9382 Caco-2 permeable - 0.6162 P-glycoprotein substrate Substrate 0.7998 P-glycoprotein inhibitor I Non-inhibitor 0.5837 P-glycoprotein inhibitor II Inhibitor 0.6045 Renal organic cation transporter Non-inhibitor 0.7573 CYP450 2C9 substrate Non-substrate 0.8268 CYP450 2D6 substrate Non-substrate 0.9078 CYP450 3A4 substrate Substrate 0.7545 CYP450 1A2 substrate Non-inhibitor 0.909 CYP450 2C9 inhibitor Non-inhibitor 0.8729 CYP450 2D6 inhibitor Non-inhibitor 0.9544 CYP450 2C19 inhibitor Non-inhibitor 0.9521 CYP450 3A4 inhibitor Non-inhibitor 0.536 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9129 Ames test Non AMES toxic 0.8938 Carcinogenicity Non-carcinogens 0.949 Biodegradation Not ready biodegradable 0.9766 Rat acute toxicity 2.5316 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9573 hERG inhibition (predictor II) Non-inhibitor 0.67
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Ketals / Alpha-hydroxy ketones / 1,3-dioxolanes / Secondary alcohols / Cyclic ketones show 5 more
- Substituents
- Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxosteroid / 3-oxo-delta-1,4-steroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / Delta-1,4-steroid show 18 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, cyclic ketal, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid, 21-hydroxy steroid (CHEBI:204734)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL: Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 Apr 28;30(17):6106-15. doi: 10.1523/JNEUROSCI.5332-09.2010. [PubMed:20427668]
- Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
- Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA: Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab. 2010 Jun;95(6):2885-91. doi: 10.1210/jc.2009-2251. Epub 2010 Apr 6. [PubMed:20371666]
Drug created on May 16, 2007 11:31 / Updated on April 23, 2018 23:08